– Older Adults With Diabetes, Hypertension, Cardiovascular Disease, and Dyslipidemia Maintained High Rates of Virologic Suppression After Switching to Biktarvy –
– Additional Data Presented Suggest the Presence of Pre-Existing Resistance in Virologically Suppressed Patients Switching to Biktarvy, Including Those With History of Treatment Failure –
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed adults ages 65 and older (n=140), including those with common comorbidities such as diabetes (22 percent), hypertension (55 percent), cardiovascular disease (24 percent), and dyslipidemia, which is an abnormal amount of lipids in the blood (59 percent). At 48 weeks, 92 percent of those who switched to Biktarvy maintained virologic suppression, achieving HIV RNA